Pengqin Chen

Pengqin Chen

Auto-generated profile, based on publicly available information

Pengqin Chen

Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, China; Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LCLingfeng Chen
Lingfeng Chen
YJYiyi Jin
Yiyi Jin
HCHongjin Chen
Hongjin Chen
CSChuchu Sun
Chuchu Sun
WFWeitao Fu
Weitao Fu
GLGuang Liang
Guang Liang

22 September 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
QZQiu-Yan Zhang
Qiu-Yan Zhang
SXSu-Jing Xu
Su-Jing Xu
JQJianchang Qian
Jianchang Qian
LYLi-Bin Yang
Li-Bin Yang
PCPeng-Qin Chen
Peng-Qin Chen
GLGuang Liang
Guang Liang
Emerging evidence shows that chronic inflammation mediated by toll-like receptors (TLRs) contributes to diabetic nephropathy. Myeloid differentiation primary-response protein-88 (MyD88) is an essential adapter protein of all TLRs except TLR3 in innate immunity. It is unclear whether MyD88 could be a therapeutic target for diabetic nephropathy. Here, we used a new small-molecule MyD88 inhibitor, LM8, to examine the pharmacological inhibition of MyD88 in protecting kidneys from inflammatory injury in diabetes. We showed that MyD88 was significantly activated in the kidney of STZ-induced type 1 diabetic mice in tubular epithelial cells as well as in high glucose-treated rat tubular epithelial cells NRK-52E. In cultured tubular epithelial cells, we show that LM8 (2.5−10 μM) or MyD88 siRNA attenuated high-concentration glucose-induced inflammatory and fibrogenic responses through inhibition of MyD88-TLR4 interaction and downstream NF-κB activation. Treatment with LM8 (5, 10 mg/kg, i.g.) significantly reduced renal inflammation and fibrosis and preserved renal function in both type 1 and type 2 diabetic mice. These renoprotective effects were associated with reduced MyD88-TLR4 complex formation, suppressed NF-κB signaling, and prevention of inflammatory factor expression. Collectively, our results show that hyperglycemia activates MyD88 signaling cascade to induce renal inflammation, fibrosis, and dysfunction. Pharmacological inhibition of MyD88 may be a therapeutic approach to mitigate diabetic nephropathy and the inhibitor LM8 could be a potential candidate for such therapy.

2 March 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
QTQidong Tang
Qidong Tang
TPTing Peng
Ting Peng
JHJie Hu
Jie Hu
TZTao Zhang
Tao Zhang
PCPengqin Chen
Pengqin Chen
GLGuang Liang
Guang Liang